Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275774 | 0.86 | MEN1 (0.49) | MAPTMEN1KMT2AGAANPSR1 | |
| SCHEMBL25496776 | 0.84 | MEN1 (0.56) | MAPTMEN1KMT2AGAANPSR1 | |
| SCHEMBL2084167 | 0.81 | MEN1 (0.46) | MAPTMEN1KMT2AGAANPSR1 | |
| SCHEMBL21751628 | 0.81 | MEN1 (0.47) | MEN1KMT2AGAATDP1CYP3A4 | |
| SCHEMBL30106033 | 0.81 | MEN1 (0.47) | MEN1KMT2AGAATDP1CYP3A4 | |
| SCHEMBL2083707 | 0.79 | MEN1 (0.46) | MAPTMEN1KMT2AGAANPSR1 | |
| SCHEMBL31059859 | 0.78 | CA12 (0.46) | MAPTMEN1KMT2AGAANPSR1 | |
| SCHEMBL28031145 | 0.78 | MEN1 (0.44) | MEN1KMT2AGAACYP3A4ALDH1A1 | |
| SCHEMBL6957779 | 0.76 | STK17B (0.49) | TDP1CYP3A4CA12CA1CA2 | |
| SCHEMBL29263638 | 0.75 | TDP1 (0.51) | NPSR1TDP1CYP3A4CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419408-A1 | 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| WO-2010119984-A1 | 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | IDO1, TPH1, AHR | MAPT 3630/4885MEN1 886/4885KMT2A 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.